Inside the American Lung Association’s Better Breathers Club

Bellerophon Presents Positive Trial Results for INOpulse in IPF-associated PH

Bellerophon Therapeutics recently presented promising new data from two Phase 2 clinical trials investigating its product INOpulse in patients with pulmonary hypertension (PH) associated with idiopathic pulmonary fibrosis (IPF), and PH associated with chronic obstructive pulmonary disease (COPD) at the American Thoracic Society 113th International Conference (ATS 2017). The INOpulse device delivers inhaled nitric oxide…

4 Things to Consider Before Getting a Service Dog

Having a service dog can greatly enhance the life of someone living with a chronic disease. They allow patients to regain some of their independence by helping with small everyday tasks like opening and closing doors, fetching meds, acting as a prop or support as their owner stands, switching on lights and attracting attention…

Understanding the Stages of Pulmonary Fibrosis

When a person is diagnosed with pulmonary fibrosis (PF), they may also go through additional tests so doctors can determine the stage of the disease. Staging of pulmonary fibrosis is important to establish the optimal treatment plan and to offer the patient an accurate prognosis. MORE: Eight of the most common lung diseases in women.  The…

Resokine Protein Reduced Lung Disease in Mice, aTyr Will Report at Conference

The resokine protein reduced interstitial lung disease (ILD) in mice, according to one of two presentations that aTyr Pharma will make at the American Thoracic Society International Conference in Washington, which starts today. Atry derived its Resolaris therapy from resokine, which helps prevent the immune system from turning against healthy cells. Scientists…

9 Tips to Lower Your Risk of Lung Disease

Lung disease is one of the main causes of American deaths, second only to heart disease. While some lung diseases are genetic and unavoidable, following a healthy lifestyle and avoiding lung irritants can help protect you from developing many of them. We’ve put together a list of tips to help lower your risk of developing a…

Genoa Secures $62 Million to Fund Phase 2 Trial of Inhaled Aerodyne for Idiopathic Pulmonary Fibrosis

Genoa Pharmaceuticals has completed a $62 million Series A financing round to pursue a Phase 2 clinical trial of Aerodone (inhaled pirfenidone) to treat idiopathic pulmonary fibrosis (IPF). The Seattle-based company also appointed Dr. Ketan Patel, Dr. Naveed Siddiqi, Tiba Aynechi, Niall O’Donnell and Dr. Heather Preston to its board of directors. Dr. Jonathan Leff,…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums